AbbVie Inc. (NYSE:ABBV) stock hit a new 52-week high Friday after the pharmaceutical company reported better-than-expected third-quarter 2026 results and raised its full-year outlook.
AbbVie reported third-quarter sales of $17.404 billion, up 10.3% year over year on a reported basis and 10.5% on an operational basis, beating the Wall Street estimate of $17.314 billion.
Adjusted earnings of $3.82 per share topped the analyst consensus estimate of $3.75.
Immunology and Neuroscience Drive Growth
AbbVie’s immunology portfolio generated $9.165 billion in sales, up 16.3% year over year, or 16.6% on an operational basis.
Skyrizi sales climbed 22.7% to $5.776 billion, while Rinvoq sales jumped 23.9% to $2.706 billion. Humira sales fell 31.2% to $683 million.
Neuroscience revenue rose 19.4% to $3.389 billion, led by Vraylar sales of $1.068 billion, up 14.3%. Botox Therapeutic generated $1.08 billion in revenue.
Oncology revenue increased 0.8% to $1.696 billion. Venclexta sales rose 10.7% to $803 million, while Imbruvica sales declined 26.1% to $522 million. Elahere revenue jumped 31% to $224 million.
Aesthetics revenue declined 1.4% to $1.176 billion, including a 1.8% decrease on an operational basis.
AbbVie Raises Dividend and Highlights Growth Strategy
AbbVie increased its quarterly dividend 5.2% to $1.82 per share from $1.73, payable Feb. 16, 2027.
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio,” said Robert Michael, chairman and CEO.
Michael highlighted key regulatory approvals, positive clinical data and the acquisition of Apogee Therapeutics as drivers of AbbVie’s long-term growth potential.
AbbVie Raises 2026 Sales and Earnings Forecasts
AbbVie raised its full-year 2026 revenue forecast to $67.8 billion from $67.6 billion, above the Wall Street estimate of $67.585 billion.
The updated outlook includes Skyrizi sales of $21.8 billion and Rinvoq sales of $10.3 billion, reflecting higher expectations for both treatments.
AbbVie also raised its neuroscience revenue forecast by $300 million to $13 billion, including $4.2 billion each from Vraylar and Botox Therapeutic and $3.1 billion from oral CGRP products.
The company increased its oncology revenue forecast to $6.6 billion, reflecting higher expected Venclexta sales of $3.1 billion, partly offset by lower Imbruvica sales of $2.1 billion.
AbbVie maintained its aesthetics revenue forecast at $5 billion, with expected Botox Cosmetic sales of $2.8 billion offsetting weakness in other aesthetics products.
The company raised its 2026 adjusted earnings forecast to $13.95-$13.99 per share from $13.76-$13.96, above the analyst consensus estimate of $13.93.
ABBV Price Action: AbbVie shares were up 1.93% at $296.41 at the time of publication on Friday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments